tiprankstipranks
Electrocore Llc (ECOR)
NASDAQ:ECOR

Electrocore (ECOR) AI Stock Analysis

Compare
910 Followers

Top Page

EC

Electrocore

(NASDAQ:ECOR)

54Neutral
Electrocore's strong revenue growth and strategic acquisitions are positive, but significant challenges in profitability and technical indicators suggest caution. The stock's valuation is unattractive due to negative earnings, and technical analysis shows bearish trends. Despite positive earnings call sentiment, the company's financial health needs improvement to boost investor confidence.
Positive Factors
Acquisition Benefits
The acquisition of NeuroMetrix is expected to be accretive to both the top and bottom line for ECOR, increasing the company’s total addressable market and diversifying its portfolio of non-invasive wellness products.
Financial Health
ECOR has no debt and has enough capital to sustain current operations, with cash and marketable securities of $12.2M.
Revenue Growth
ECOR's strong performance in 4Q24 marked its ninth consecutive quarter of record revenue, reflecting deeper penetration within the VA/DoD channel and broader adoption of its Truvaga line of OTC wellness devices.
Negative Factors
Lack of Guidance
The stock decline is mostly attributed to the company not issuing forward guidance, which it has done in the past.
Supply Chain Risks
There is potential for the VA/DoD channel to soften due to uncertainties related to possible reductions of supply chain staff in the VA system.

Electrocore (ECOR) vs. S&P 500 (SPY)

Electrocore Business Overview & Revenue Model

Company DescriptionelectroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
How the Company Makes MoneyElectrocore generates revenue primarily through the sale of its gammaCore device and related accessories. The company targets revenue streams from both healthcare professionals and consumers. It sells its products directly to healthcare providers, who then offer them to patients, as well as directly to consumers through various distribution channels. Electrocore also engages in partnerships and collaborations with healthcare organizations to expand its market reach and product adoption. Reimbursement from insurance coverage and expanding indications for the use of its nVNS therapy are significant factors that contribute to its earnings.

Electrocore Financial Statement Overview

Summary
Electrocore has demonstrated impressive revenue growth, but profitability remains a challenge with negative net income and EBIT margins. The balance sheet shows a high level of liabilities and the company relies on external financing due to negative cash flows.
Income Statement
65
Positive
Electrocore has shown a consistent growth in revenue over the years, with a notable increase from $2.39 million in 2019 to $25.18 million in 2024. However, the company is still facing significant profitability challenges, as evidenced by negative net income and EBIT margins across the years. Despite the revenue growth, the company has not yet achieved positive net profit margins or EBIT margins, indicating that cost control and operational efficiency are areas for improvement.
Balance Sheet
60
Neutral
The company's balance sheet reflects a relatively high level of liabilities compared to its equity, with a debt-to-equity ratio of 0.55 in 2024. Stockholders' equity has remained relatively stable from 2023 to 2024, but the equity ratio has decreased due to a rise in total liabilities. The company maintains a reasonable cash position, which provides some liquidity cushion. However, the consistent negative net income impacts the overall return on equity.
Cash Flow
55
Neutral
Electrocore's cash flow situation shows significant negative operating cash flows, indicating that the company has not yet reached a sustainable cash-generating position from its core operations. Free cash flow has improved slightly but remains negative, suggesting that the company is still reliant on external financing to support its operations and growth. The operating cash flow to net income ratio is poor due to persistent negative earnings.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
25.18M16.03M8.59M5.45M3.50M
Gross Profit
21.40M13.23M6.98M4.07M1.76M
EBIT
-12.16M-18.80M-22.87M-20.04M-24.28M
EBITDA
-12.16M-17.76M-22.33M-19.66M-24.18M
Net Income Common Stockholders
-11.89M-18.83M-22.16M-17.22M-23.51M
Balance SheetCash, Cash Equivalents and Short-Term Investments
11.97M10.33M17.71M34.69M22.63M
Total Assets
20.47M16.10M24.76M42.83M31.52M
Total Debt
4.14M626.00K699.00K760.87K2.99M
Net Debt
686.00K-9.71M-17.01M-33.93M-1.25M
Total Liabilities
12.93M8.66M7.67M6.18M7.87M
Stockholders Equity
7.54M7.44M17.09M36.65M23.64M
Cash FlowFree Cash Flow
-6.95M-14.87M-16.64M-13.63M-20.10M
Operating Cash Flow
-6.95M-14.67M-16.64M-13.63M-20.10M
Investing Cash Flow
-8.52M-206.00K0.0018.22M-7.96M
Financing Cash Flow
8.44M7.49M0.0025.68M18.95M

Electrocore Technical Analysis

Technical Analysis Sentiment
Negative
Last Price6.69
Price Trends
50DMA
13.86
Negative
100DMA
13.82
Negative
200DMA
10.33
Negative
Market Momentum
MACD
-2.28
Positive
RSI
18.99
Positive
STOCH
10.19
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ECOR, the sentiment is Negative. The current price of 6.69 is below the 20-day moving average (MA) of 9.92, below the 50-day MA of 13.86, and below the 200-day MA of 10.33, indicating a bearish trend. The MACD of -2.28 indicates Positive momentum. The RSI at 18.99 is Positive, neither overbought nor oversold. The STOCH value of 10.19 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ECOR.

Electrocore Risk Analysis

Electrocore disclosed 125 risk factors in its most recent earnings report. Electrocore reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Electrocore Peers Comparison

Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
ZBZBH
73
Outperform
$22.35B25.337.24%0.85%3.84%-9.29%
56
Neutral
$2.13B34.084.87%8.33%256.54%
54
Neutral
$46.40M-158.63%57.09%52.18%
53
Neutral
$766.22M-913.07%31.76%24.85%
50
Neutral
$9.12M-45.38%-48.61%32.18%
48
Neutral
$6.84B1.02-53.11%2.50%16.84%0.92%
43
Neutral
$248.12M-139.60%4.96%-29.29%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ECOR
Electrocore
6.69
0.80
13.58%
NURO
Neurometrix
4.42
0.46
11.62%
ZBH
Zimmer Biomet Holdings
113.18
-14.16
-11.12%
LIVN
LivaNova
39.28
-15.04
-27.69%
EOLS
Evolus
12.03
-1.73
-12.57%
STIM
Neuronetics
3.68
-0.86
-18.94%

Electrocore Earnings Call Summary

Earnings Call Date: Mar 12, 2025 | % Change Since: -48.54% | Next Earnings Date: May 1, 2025
Earnings Call Sentiment Positive
The earnings call highlighted strong revenue growth, particularly in the VA channel and Truvaga sales, alongside improved financial metrics and strategic acquisitions. However, challenges were noted in the TAC-STIM product line, flat revenue in non-U.S. markets, and slower-than-expected progress in the Kaiser channel.
Highlights
Significant Revenue Growth
ElectroCore reported a revenue of $25.2 million for 2024, up 57% from the previous year, marking their ninth consecutive record revenue quarter with a 36% increase in Q4 over the prior year.
Strong Performance in VA Channel
Sales in the VA channel grew 85% to $17.8 million for the full year 2024, with Q4 sales increasing by 47% compared to the same quarter in 2023.
Truvaga Sales Surge
Truvaga net sales in 2024 were $2.8 million, representing a 174% increase over 2023, with a 271% increase in Q4 2024 compared to Q4 2023.
Improved Financial Metrics
Full year gross margins increased to 85% from 83% last year, and net loss narrowed by 37%.
Strategic Acquisitions
Acquisition of NeuroMetrix and a distribution agreement with Spark Biomedical aim to enhance the product portfolio in bioelectronic health and wellness.
Lowlights
Decline in TAC-STIM Sales
TAC-STIM sales decreased to $1.2 million in 2024 from $1.7 million in 2023.
Flat Revenue in Non-U.S. Markets
Revenue from channels outside the U.S. remained flat at $1.9 million for 2024 compared to $1.8 million in 2023.
Challenges with Kaiser Channel
Progress with the Joerns and Kaiser channel has been slower than expected, with only one or two prescriptions per month.
Company Guidance
During the electroCore earnings call for the fiscal year 2024, CEO Dan Goldberger provided an extensive overview of the company's financial performance and strategic direction. The company reported a revenue of $25.2 million for the year, marking a 57% increase, with gross margins of 85%, up from 83% the previous year. electroCore's gammaCore products saw significant growth, particularly in the VA channel, which grew 85% year-over-year to $17.8 million. The Truvaga brand, launched in 2023, also showed robust performance with net sales reaching $2.8 million, a 174% increase over the prior year. The company narrowed its net loss by 37% and is making progress towards positive cash flow from operations. Goldberger highlighted the acquisition of NeuroMetrix, expected to close in Q2 2025, as a strategic move to enhance their bioelectronic health and wellness portfolio. He also noted the launch of Truvaga Plus on Amazon and the expansion into new distribution channels, aiming for sustained growth and leveraging established sales channels.

Electrocore Corporate Events

Executive/Board Changes
Electrocore Board Restructures After Director Resignation
Neutral
Feb 28, 2025

On February 24, 2025, Charles S. Theofilos, M.D., resigned from his roles at Electrocore, Inc., including his position as a Class III director and memberships in the Compensation and Nominating and Governance Committees. Following his resignation, the Board reduced its size from eight to seven members, effective February 28, 2025.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.